News

A new clinical trial evaluating the efficacy of nucresiran in treating transthyretin amyloid cardiomyopathy (ATTR-CM) is set to launch soon.

Patisiran led to improved functional status and quality of life among patients with ATTR-CM.

For patients with ATTR-CM, nerve symptoms — known as autonomic dysfunction — could be a warning sign of more serious heart trouble ahead.

AI may be a game changer when it comes to recognizing and diagnosing cardiac amyloidosis, according to a new study.

The use of SGLTis, a drug class commonly prescribed for diabetes and heart failure, appears to decrease mortality in ATTR-CM.

The physical force of blood flow may contribute to the development of transthyretin amyloid cardiomyopathy (ATTR-CM).

New research finds elevated levels of the liver enzyme GGT may help predict severity and outcomes in people with ATTR-CM.

Tailored exercise programs can reduce symptoms and improve quality of life in patients with HFpEF, including those with ATTR-CM.

A new study found that patients of Afro-Caribbean descent who have ATTR-CM have worse health outcomes, emphasizing the need for better care.

Measuring levels of hepatocyte growth factor (HGF) in the blood may help diagnose cardiac amyloidosis, including ATTR-CM.